FTO and nonpapillary renal cell carcinoma: To determine whether FTO inhibition increased DNA damage in ccRCC cells through decreased pyrimidines and/or increased ROS, we treated the cells with FB23-2, pyrimidine nucleobases, the antioxidant N-acetylcysteine (NAC), or both pyrimidine nucleobases and NAC.